Age-Associated Cross-reactive Antibody-Dependent Cellular Cytotoxicity Toward 2009 Pandemic Influenza A Virus Subtype H1N1

Journal of Infectious Diseases

Volumn 208, Issue 7, 2013, Pages 1051-1061

  Jegaskanda, Sinthujan ^a   Laurie, Karen L ^b   Amarasena, Thakshila H ^a   Winnall, Wendy R ^a   Kramski, Marit ^a   De Rose, Robert ^a   Barr, Ian G ^b   Brooks, Andrew G ^a   Reading, Patrick C ^a,b   Kent, Stephen J ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

Author keywords

ADCC; influenza; NK cells; swine origin influenza virus

Indexed keywords

GAMMA INTERFERON; INFLUENZA VIRUS HEMAGGLUTININ; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; VIRUS ANTIBODY;

2009 H1N1 INFLUENZA; ADOLESCENT; ADULT; AGE; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY TITER; ARTICLE; CELL KILLING; CHILD; CONTROLLED STUDY; CROSS REACTION; EPITHELIUM CELL; HEMAGGLUTINATION INHIBITION; HUMAN; HUMAN CELL; INFLUENZA VIRUS A H1N1; MIDDLE AGED; NATURAL KILLER CELL; NONHUMAN; PANDEMIC; PRESCHOOL CHILD; PRIORITY JOURNAL; VIRAL CLEARANCE; FEMALE; IMMUNOLOGY; INFANT; INFLUENZA; MALE; NK CELLS; SWINE-ORIGIN INFLUENZA VIRUS; VIROLOGY;

ADCC; INFLUENZA; NK CELLS; SWINE-ORIGIN INFLUENZA VIRUS;

ADOLESCENT; ADULT; AGE FACTORS; ANTIBODIES, VIRAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84887266053     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit294     Document Type: Article

References (39)

1. Dawood FS, Jain S, Finelli L, et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009; 360:2605-15
2. Chowell G, Bertozzi SM, Colchero MA, et al. Severe respiratory disease concurrent with the circulation of H1N1 influenza. N Engl J Med 2009; 361:674-9
3. Webb SA, Pettila V, Seppelt I, et al. Critical care services and 2009 H1N1 influenza in Australia and New Zealand. N Engl J Med 2009; 361:1925-34
4. Jain S, Kamimoto L, Bramley AM, et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med 2009; 361:1935-44
5. Cao B, Li XW, Mao Y, et al. Clinical features of the initial cases of 2009 pandemic influenza A (H1N1) virus infection in China. N Engl J Med 2009; 361:2507-17
6. Jacobs JH, Archer BN, Baker MG, et al. Searching for sharp drops in the incidence of pandemic A/H1N1 influenza by single year of age. PLoS One 2012; 7:e42328
7. Fisman DN, Savage R, Gubbay J, et al. Older age and a reduced likelihood of 2009 H1N1 virus infection. N Engl J Med 2009; 361:2000-1
8. Miller E, Hoschler K, Hardelid P, Stanford E, Andrews N, Zambon M. Incidence of 2009 pandemic influenza A H1N1 infection in England: A cross-sectional serological study. Lancet 2010; 375:1100-8
9. McVernon J, Laurie K, Nolan T, et al. Seroprevalence of 2009 pandemic influenza A(H1N1) virus in Australian blood donors, October-December 2009. Euro Surveill 2010; 15:1-8
10. Kelly HA, Grant KA, Fielding JE, et al. Pandemic influenza H1N1 2009 infection in Victoria, Australia: No evidence for harm or benefit following receipt of seasonal influenza vaccine in 2009. Vaccine 2011; 29: 6419-26
11. O'Donnell CD, WrightA, Vogel LN, Wei CJ, Nabel GJ, SubbaraoK. Effect of priming with H1N1 influenza viruses of variable antigenic distances on challenge with 2009 pandemic H1N1 virus. J Virol 2012; 86:8625-33
12. Manicassamy B, Medina RA, Hai R, et al. Protection of mice against lethal challenge with 2009 H1N1 influenza A virus by 1918-like and classical swine H1N1 based vaccines. PLoS Pathog 2010; 6:e1000745
13. Xu R, Ekiert DC, Krause JC, Hai R, Crowe JE Jr, Wilson IA. Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus. Science 2010; 328:357-60
14. Easterbrook JD, Kash JC, Sheng ZM, et al. Immunization with 1976 swine H1N1-or 2009 pandemic H1N1-inactivated vaccines protects mice from a lethal 1918 influenza infection. Influenza Other Respi Viruses 2011; 5:198-205
15. Medina RA, Manicassamy B, Stertz S, et al. Pandemic 2009 H1N1 vaccine protects against 1918 Spanish influenza virus. Nature Commun 2010; 1:28
16. Liu J, Zhang S, Tan S, et al. Cross-Allele cytotoxic T lymphocyte responses against 2009 pandemic H1N1 influenza A virus among HLA-A24 and HLA-A3 supertype-positive individuals. J Virol 2012; 86:13281-94
17. Weinfurter JT, Brunner K, Capuano SV 3rd, et al. Cross-reactive T cells are involved in rapid clearance of 2009 pandemic H1N1 influenza virus in nonhuman primates. PLoS Pathog 2011; 7:e1002381
18. Carter DM, Bloom CE, Nascimento EJ, et al. Sequential seasonal H1N1 influenza virus infections protect ferrets against novel 2009 H1N1 influenza virus. J Virol 2013; 87:1400-10
19. Skountzou I, Koutsonanos DG, Kim JH, et al. Immunity to pre-1950 H1N1 influenza viruses confers cross-protection against the pandemic swine-origin 2009 A (H1N1) influenza virus. J Immunol 2010; 185: 1642-9
20. Corti D, Voss J, Gamblin SJ, et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 2011; 333:850-6
21. Hancock K, Veguilla V, Lu X, et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009; 361:1945-52
22. Wei CJ, Boyington JC, Dai K, et al. Cross-neutralization of 1918 and 2009 influenza viruses: Role of glycans in viral evolution and vaccine design. Sci Transl Med 2010; 2:24ra21
23. O'Brien KB, Morrison TE, Dundore DY, Heise MT, Schultz-Cherry S. A protective role for complement C3 protein during pandemic 2009 H1N1 and H5N1 influenza Avirus infection. PLoS One 2011; 6:e17377
24. Ohta R, Torii Y, Imai M, Kimura H, Okada N, Ito Y. Serum concentrations of complement anaphylatoxins and proinflammatory mediators in patients with 2009 H1N1 influenza. Microbiol Immunol 2011; 55:191-8
25. Huber VC, Lynch JM, Bucher DJ, Le J, Metzger DW. Fc receptormediated phagocytosis makes a significant contribution to clearance of influenza virus infections. J Immunol 2001; 166:7381-8
26. Hashimoto G, Wright PF, Karzon DT. Antibody-dependent cellmediated cytotoxicity against influenza virus-infected cells. J Infect Dis 1983; 148:785-94
27. Hashimoto G, Wright PF, Karzon DT. Ability of human cord blood lymphocytes to mediate antibody-dependent cellular cytotoxicity against influenza virus-infected cells. Infect Immun 1983; 42:214-8
28. Greenberg SB, Criswell BS, Six HR, Couch RB. Lymphocyte cytotoxicity to influenza virus-infected cells: Response to vaccination and virus infection. Infect Immun 1978; 20:640-5
29. Vella S, Rocchi G, Resta S, Marcelli M, De Felici A. Antibody reactive in antibody-dependent cell-mediated cytotoxicity following influenza virus vaccination. J Med Virol 1980; 6:203-11
30. Jegaskanda S, Job ER, Kramski M, et al. Cross-reactive influenzaspecific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies. J Immunol 2013; 190:1837-48
31. Rockman S, Brown LE, Barr IG, et al. Neuraminidase-inhibiting antibody is a correlate of cross-protection against lethal H5N1 influenza in ferrets immunised with seasonal influenza vaccine. J Virol 2013; 87:3053-61
32. Jegerlehner A, Schmitz N, Storni T, Bachmann MF. Influenza Avaccine based on the extracellular domain of M2: Weak protection mediated via antibody-dependent NK cell activity. J Immunol 2004; 172:5598-605
33. Chung AW, Isitman G, Navis M, et al. Immune escape from HIVspecific antibody-dependent cellular cytotoxicity (ADCC) pressure. Proc Natl Acad Sci U S A 2011; 108:7505-10
34. Isitman G, Chung AW, Navis M, Kent SJ, Stratov I. Pol as a target for antibody dependent cellular cytotoxicity responses in HIV-1 infection. Virology 2011; 412:110-6
35. Hirst GK. Studies of antigenic differences among strains of influenza a by means of red cell agglutination. J Exp Med 1943; 78:407-23
36. Laurie KL, Carolan LA, Middleton D, Lowther S, Kelso A, Barr IG. Multiple infections with seasonal influenza A virus induce crossprotective immunity against A(H1N1) pandemic influenza virus in a ferret model. J Infect Dis 2010; 202:1011-20
37. Khurana S, Verma N, Talaat KR, Karron RA, Golding H. Immune response following H1N1pdm09 vaccination: Differences in antibody repertoire and avidity in young adults and elderly populations stratified by age and gender. J Infect Dis 2012; 205:610-20
38. Khurana S, Frasca D, Blomberg B, Golding H. AID activity in B cells strongly correlates with polyclonal antibody affinity maturation in-vivo following pandemic 2009-H1N1 vaccination in humans. PLoS Pathog 2012; 8:e1002920
39. Verma N, Dimitrova M, Carter DM, et al. Influenza virus H1N1pdm09 infections in the young and old: Evidence of greater antibody diversity and affinity for the hemagglutinin globular head domain (HA1 domain) in the elderly than in young adults and children. J Virol 2012; 86:5515-22